Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Shares Purchased by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC raised its position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) by 33.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 800,000 shares of the company’s stock after acquiring an additional 200,000 shares during the quarter. Affinity Asset Advisors LLC’s holdings in Aerovate Therapeutics were worth $2,120,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. ADAR1 Capital Management LLC grew its position in shares of Aerovate Therapeutics by 720.7% during the fourth quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company’s stock worth $2,459,000 after buying an additional 814,941 shares in the last quarter. Deltec Asset Management LLC purchased a new stake in shares of Aerovate Therapeutics in the 4th quarter valued at approximately $514,000. FMR LLC raised its holdings in shares of Aerovate Therapeutics by 54,095.4% in the 3rd quarter. FMR LLC now owns 82,919 shares of the company’s stock valued at $173,000 after purchasing an additional 82,766 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of Aerovate Therapeutics during the 4th quarter worth $198,000. Finally, JPMorgan Chase & Co. increased its holdings in Aerovate Therapeutics by 1,021.1% in the fourth quarter. JPMorgan Chase & Co. now owns 67,165 shares of the company’s stock valued at $178,000 after buying an additional 61,174 shares during the last quarter.

Aerovate Therapeutics Trading Up 1.9 %

AVTE stock opened at $2.71 on Tuesday. The company’s 50 day moving average is $2.49 and its two-hundred day moving average is $2.49. The stock has a market cap of $78.55 million, a P/E ratio of -0.91 and a beta of 0.95. Aerovate Therapeutics, Inc. has a twelve month low of $1.25 and a twelve month high of $25.58.

Aerovate Therapeutics (NASDAQ:AVTE) last announced its earnings results on Thursday, March 27th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). On average, equities research analysts predict that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current year.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.